Supplement firms face injunction for health claims
This article was originally published in The Tan Sheet
Executive Summary
FDA announces a permanent injunction against Brownwood Acres Foods and Cherry Capital Services, and two of their executives as a result of unapproved drug claims and unauthorized health claims about their products, which include liquid glucosamine and salmon oil capsules, agency reports Feb. 22. According to FDA, the firms and executives agreed to a consent decree that prohibits them from manufacturing and distributing products claimed to "cure, treat, mitigate or prevent diseases." Signed by a U.S. District Court in Michigan, the decree requires the firms to remove the claims from the labels of products, Web sites and brochures, and hire an expert to review claims. FDA notes firms cannot make such claims until products "are approved by the FDA as new drugs, exempt from approval as investigational new drugs, or until the claims on the products' label ... comply with the law"...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.